title: Development of stable influenza vaccine powder formulations: challenges and possibilities.
abstract: Influenza vaccination represents the cornerstone of influenza prevention. However, today all influenza vaccines are formulated as liquids that are unstable at ambient temperatures and have to be stored and distributed under refrigeration. In order to stabilize influenza vaccines, they can be brought into the dry state using suitable excipients, stabilizers and drying processes. The resulting stable influenza vaccine powder is independent of cold-chain facilities. This can be attractive for the integration of the vaccine logistics with general drug distribution in Western as well as developing countries. In addition, a stockpile of stable vaccine formulations of potential vaccines against pandemic viruses can provide an immediate availability and simple distribution of vaccine in a pandemic outbreak. Finally, in the development of new needle-free dosage forms, dry and stable influenza vaccine powder formulations can facilitate new or improved targeting strategies for the vaccine compound. This review represents the current status of dry stable inactivated influenza vaccine development. Attention is given to the different influenza vaccine types (i.e. whole inactivated virus, split, subunit or virosomal vaccine), the rationale and need for stabilized influenza vaccines, drying methods by which influenza vaccines can be stabilized (i.e. lyophilization, spray drying, spray-freeze drying, vacuum drying or supercritical fluid drying), the current status of dry influenza vaccine development and the challenges for ultimate market introduction of a stable and effective dry-powder influenza vaccine.
authors.affiliation: Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands.
authors.forename: J-P
authors.initials: JP
authors.lastname: Amorij
authors.forename: A
authors.initials: A
authors.lastname: Huckriede
authors.forename: J
authors.initials: J
authors.lastname: Wilschut
authors.forename: H W
authors.initials: HW
authors.lastname: Frijlink
authors.forename: W L J
authors.initials: WL
authors.lastname: Hinrichs
mesh_terms: D004355:Drug Stability; D005612:Freeze Drying; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000737:chemistry / Q000276:immunology; D011208:Powders; D014613:Vaccines, Attenuated / Q000276:immunology
chemical_list: D007252:Influenza Vaccines; D011208:Powders; D014613:Vaccines, Attenuated